AR and hepatocellular carcinoma: AR-SV expression is thought to be upregulated in castration-resistant prostate cancer (CRPC) through selective pressure from androgen deprivation therapy (ADT) while HCC expresses AR-SVs in patients absent selective pressure from low levels of circulating androgens or anti-androgen therapy [20,44].